AVX 13616 is primarily utilized in the field of pharmaceutical research and development, particularly in the study of antiviral therapies. It has shown potential in inhibiting specific viral enzymes, making it a candidate for the treatment of viral infections. Researchers are exploring its efficacy in targeting viruses that are resistant to existing treatments, aiming to develop more effective antiviral drugs. Additionally, AVX 13616 is being investigated for its role in combination therapies, where it may enhance the overall effectiveness of treatment regimens. Its application extends to preclinical studies, where it is used to understand the mechanisms of viral replication and to identify new therapeutic targets.